Quarterly ResultAug 6, 2026, 07:32 AM
Compass Therapeutics Q2 Net Loss $25.2M; Provides Pipeline Update
AI Summary
Compass Therapeutics reported a net loss of $25.2 million for the second quarter of 2026, an increase from $19.9 million in the same period last year. The company maintained a strong cash position with $180 million in cash and marketable securities, providing a runway into 2028. Significant pipeline progress was highlighted, including expected FDA feedback on tovecimig Phase 2/3 data, an oral presentation at ESMO, active enrollment for CTX-8371 cohort expansions, initial dosing for CTX-10726 Phase 1, and planned initiation of CTX-471 Phase 2.
Key Highlights
- Q2 2026 net loss was $25.2 million, compared to $19.9 million in Q2 2025.
- Net loss per share for Q2 2026 was $0.13, compared to $0.14 in Q2 2025.
- Cash and marketable securities totaled $180 million as of June 30, 2026.
- Cash runway is anticipated to fund operations into 2028.
- Q2 2026 R&D expenses increased 19% to $19.6 million.
- Q2 2026 G&A expenses increased 59% to $7.4 million.
- Tovecimig Phase 2/3 data showed an improved overall response rate (ORR) of 18.0% (20/111 patients).
- The p-value for tovecimig ORR improved to 0.0228 compared to paclitaxel alone.
Price Impact
More from CMPX